News
Nuffield Health and GE HealthCare launch major diagnostic imaging hub in Oxford
Nuffield Health and GE HealthCare have launched a major new diagnostic hub at Nuffield Health The Manor Hospital in Oxford. Equipped with the latest generation of imaging technology from GE HealthCare, the hub will expand access to provide faster, more accurate and advanced diagnostics for people from the local community. This new diagnostic hub at The Manor Hospital
in Oxford is equipped with the latest AI-enabled imaging systems. With the hospital offering services to both NHS and private patients, people from across the region will benefit from earlier detection of diseases including cancer, faster progression to the right treatment and improved clinical outcomes. As part of this, the hospital is enhancing its
cardiac service, with access to cutting-edge CT and MRI systems. This will help diagnose and treat more complex heart conditions, with cardiologists delivering pacemakers, ICDs and heart failure devices from their state-of-the-art facility. The new diagnostic hub was launched at a
celebration event attended by the Mayoress of Oxford, senior leaders from Nuffield Health and GE HealthCare, and representatives from local NHS organisations – who received a tour and live
the cardiology service at The Manor Hospital, enabling us to diagnose and manage even complex heart conditions more quickly and accurately – giving patients access to specialist care sooner.” This development marks the first anniversary of
the 20-year, £200 million collaboration, to deliver an industry-leading diagnostic and imaging service across Nuffield Health’s UK-wide hospital network. Diagnostics remains one of the biggest
The Lord Mayor, Louise Upton, opening the diagnostic imaging hub.
demonstration of the new technology. Mr Kim Rajappan consultant cardiologist at
The Manor Hospital, said: “The launch of this new diagnostic hub is fantastic news for patients across Oxfordshire and beyond. The Manor Hospital works closely with the NHS and health insurers to deliver care to patients across the region, and this added diagnostic capacity will help improve access, reduce delays, and deliver the best possible care for our community. “The technology will also significantly strengthen
bottlenecks in the UK healthcare system, with 1.7 million patients currently waiting for diagnostic tests - an increase of 70% since before the pandemic - and nearly one in four waiting longer than the Government’s six-week target. Speaking at the launch in Oxford, Alex Perry, CEO
of Nuffield Health, said: “Our ambition at Nuffield Health is to provide the best care and support that patients can get anywhere, and this facility represents a major step forward in delivering on that commitment. “The arrival of the latest AI-empowered imaging
systems will allow our clinicians to work with even greater precision and give patients vital answers about their health sooner, and with more confidence.”
Roll out of innovative bowel cancer screening test
An innovative bowel cancer screening test created in the north east is now being rolled out for patients elsewhere in the country. The test allows improved and faster testing
for Lynch syndrome, a hereditary condition which brings increased risk of certain types of cancer, including colorectal. Designed by a team of scientists from Newcastle Hospitals and Newcastle University led by Professor of clinical genetics, Sir John Burn, the test is being made available for patients across west Yorkshire and the Humber, and Bristol in the south west. This follows the north east and north Cumbria where the test has been used since 2022. Screening for Lynch syndrome means that if a person tests positive, a DNA test can then be offered to their relatives to see who else has the condition, so they can be put on a regular programme of checks. Julien Deckard, 56, of Ingleton near Darlington, has had bowel cancer three times in the last fifteen years and has had multiple surgeries and chemotherapy at the Freeman Hospital. He was tested for Lynch syndrome and found to be positive. “It’s five years since I had an operation to remove cancer for the second time. It was then that I was
Newcastle Hospitals to be UKCA-marked, meaning it is certified to be sold in the UK. Last year the team won an award from Cancer
Research Horizons, the innovation arm of Cancer Research UK, in recognition of their impact in transforming diagnosis for patients. Alessia Errico, associate director of search
tested for Lynch syndrome, and I was advised that my children could be carriers as well. “It was good to know about this and have more information about the increased risk of colorectal cancer. I’m monitored regularly with blood tests every three or four months and I have a CT scan every year. One of my daughters tested positive and she’s now monitored regularly. While it’s sad I’ve passed this on, it’s reassuring that there’s regular monitoring and early detection for my family if they need it.” The test known as the MSI plus assay detects
a pattern of chemical changes on DNA which can indicate the condition. It is the first product of
and evaluation at Cancer Research Horizons, said of the award: “We named the MSI plus assay as our Translational Project of the Year because it exemplifies the kind of innovation that can truly transform patient care. “The Newcastle team’s work is a model for how
research and clinical practice can come together to improve outcomes for people affected by cancer.” Meeting recommendations by the National
Institute for Health and Care Excellence, the test is being used by scientists in some of NHS England’s genomics laboratory hubs across the country. Dr. Ciaron McAnulty, clinical scientist at
Newcastle Hospitals, said: “The test has significantly improved how we identify people at risk of Lynch syndrome, with faster screening enabling more patients to be diagnosed in a shorter time frame, resulting in better monitoring of those at higher risk of developing cancer.”
March 2026 I
www.clinicalservicesjournal.com 11
appledesign -
stock.adobe.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64
